- Extensive apoptosis of malignant cells
- Decreased tumor invasiveness and metastasis
- Decreased tumor and endothelial cell proliferation
- Blockade of metastatic bone lesion progression
- Disruption of tumor vasculature
Previously studies already showed improvement from use of Exelixis's Cabometyx over Pfizer's Sutent in treating kidney cancer patients.
Jim Cramer is bullish on Carnival, Tableau Software, Groupon, Newell Brands and more.
Jim Cramer says the earnings results we get this week will determine where stocks are headed for the rest of the quarter.